While the pharmaceutical industry's products have extended and improved life, it has also restricted access to those products, contributing to several decades of increasing health-care costs. As Joseph Gabriel shows in Medical Monopoly: Intellectual Property Rights and the Origins of the Modern Pharmaceutical Industry, drug restriction has a complex past rooted in changing norms for the protection of intellectual property that came of age during the Gilded Age and Progressive Era.
Gabriel's work is part of an emerging body of literature that locates the process of drug development inside and outside of the laboratory. He explains how the consolidation of medical authority, the emergence of corporate capitalism, and the growing role of courts intermeshed over the course of the nineteenth and early twentieth centuries to influence contemporary understandings of intellectual property.
The first two chapters of Medical Monopoly describe the relationship between therapeutics and patenting prior to the Civil War. For regular physicians, the idea of using patented therapeutics was antithetical to a belief that medical science should be “a gradual process … built on a renunciation of profit and a free circulation of knowledge within a community of respectable peers” (59). Patents restricted necessary information about a product, undermining the public good. This dislike of patenting was both principled and self-interested—Gabriel reminds the reader that the rhetoric of regular physicians was tied to the fight over control of the chaotic antebellum medical market.
On the other end of the spectrum, purveyors of nostrums were also deeply opposed to patenting their discoveries. Here the quest for profit drove decision making. Legal precedent held that patents could not be issued for “principles of nature” but only for the processes that fundamentally transformed them (15–16). Thus, it was unclear if many botanical medicines could be legally protected. Because an important part of the patent application was a requirement to disclose ingredients, many irregular physicians and druggists chose to keep their formulas secret as a way to protect their commercial livelihoods.
The period from Reconstruction through the Gilded Age saw a major shift in the relationship between patent protection and the free exchange of medical knowledge. The pharmaceutical industry was caught up in the same process of capital accumulation and expansion as other businesses. Yet it remained split into its antebellum configuration: respected firms served orthodox medicine and other firms provided therapeutics for irregular physicians and the home care market. Further complicating the picture was a business model where most ethical firms refused to bring new drugs to market unless their physician clients had already deemed a remedy safe and effective through clinical experimentation (69). The game changer for the ethical firms was the decision by the Detroit-based Parke, Davis and Company to challenge this practice by aggressively researching new therapeutic agents and working to bring them to market on their own. What made these actions palatable to the orthodox medical community were two key decisions—the creation of a “working bulletin system” to openly disseminate the results of the firm's research, and eschewing patent protection for these new products (89–91,115–16).
This quest for formal structure and official sanction was largely ignored by firms that supported the irregular medical community or produced home remedies. These firms felt little need to placate the forces of scientific medicine. The preservation of market share, rather than safety or efficacy, was their primary concern. Thus these firms turned to trademarking as a way to protect the name, if not the content of their therapeutics during the Gilded Age and early Progressive Eras. As Gabriel notes, however, this was an imperfect solution to the problem of intellectual property protection as courts and markets both struggled to define what parts of brand names trademarks protected (176–78).
What finally caused the pharmaceutical industry to embrace patent and trademark law were two important Progressive Era changes. The first was the increasing volume of synthetic therapeutics coming from Germany. Because many of these therapeutics came from companies that produced chemicals, their creators often followed norms in their own industry, which was to patent and trademark their products. This caused a serious problem for many orthodox physicians: synthetic therapeutics were highly effective and quickly became “widely recognized as staples of good medical care,” but their patents and trademarks caused dyspepsia for orthodox physicians (200). The solution to this problem was a growing acceptance that laboratory tests could supplement the older model of clinical experimentation as an additional test for drug efficacy and safety (157). These new practices intersected with the federal regulation of drugs through acts like the Pure Food and Drug Act of 1906 (222–30).
The seizure of German patents by the Office of Alien Property in 1918 highlighted the important role that patent and trademark protection now played in the pharmaceutical industry. Drawing from the reflections of former pharmaceutical executive Joseph Stieglitz, Gabriel argues that the patent seizure was undertaken at least in part to invalidate German trade names and give the U.S. firms equal footing in the postwar marketplace. By exploiting these seized patients, Gabriel notes that “the ethical wing of the industry expanded rapidly during the 1920s” and that through this expansion the industry came to see the financial and social value of patents and trademarks (239–40). Thus, by the postwar years, the meaning of patent protection in the pharmaceutical market had effectively been reversed—from a marker of dubious quality and individual advantage in the years surrounding the Civil War to a necessary precaution that assured quality and unfettered access. Once this new line of reasoning was accepted, it opened the door for the new drug development model, which emerged during the 1920s and 1930s, that privileged close cooperation between private industry and academe.
Medical Monopoly fills an important role in the social history of science and medicine by showing the shifting relationship among public policy, medical practice, consumerism, and self-interest. This wider focus enriches our understanding of the origins of the modern system of intellectual property and shows how big pharma became such a critical part of the modern health-care landscape.
